Picard Medical, Inc. (PMI)
NYSEAMERICAN: PMI · Real-Time Price · USD
0.1628
+0.0069 (4.43%)
Jun 30, 2026, 2:13 PM EDT - Market open
Company Description
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure.
The company operates in the United States, Europe, and internationally. The company was incorporated in 2021 and is headquartered in Tucson, Arizona.
Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc.
Picard Medical, Inc.
| Country | United States |
| Founded | 1981 |
| IPO Date | Aug 29, 2025 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Yuncai Fang |
Contact Details
Address: 1992 East Silverlake Road Tucson, Arizona 85713 United States | |
| Phone | 520 545 1234 |
| Website | picardmedical.com |
Stock Details
| Ticker Symbol | PMI |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 2030617 |
| CUSIP Number | 71953R108 |
| ISIN Number | US71953R1086 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Patrick N. J. Schnegelsberg | Chief Executive Officer and Director |
| Matthew Schuster | Chief Operating Officer |
| Georgina Smith | Chief Accounting Officer |
| Dr. Frank Tinker Ph.D. | Chief Technology Officer of SynCardia Systems, LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 29, 2026 | 8-K | Current Report |
| Jun 29, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 15, 2026 | PRE 14A | Other preliminary proxy statements |
| Jun 5, 2026 | SCHEDULE 13G/A | Filing |
| Jun 3, 2026 | 144 | Filing |
| Jun 2, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144 | Filing |
| Jun 1, 2026 | 424B3 | Prospectus |
| May 29, 2026 | EFFECT | Notice of Effectiveness |